Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Regenex Pharmaceutical
- Ownership
- Private
- Development stage
- Other
01
Overview
Regenerex’s products have demonstrated high rates of complete closure for chronic wounds within 90 days in multiple clinical evaluations. Their approach focuses on modulating the cellular environment of chronic wounds using their proprietary QBx™ technology.
- Therapeutic areas
- EndocrinologyDermatology
- Modalities
- Topical biologic dressings and proprietary wound healing formulas using QBx™ technology
- Industry
- Biotech
Beyond the preview
Go deeper on Regenex Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Regenex Pharmaceutical.